A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Miels will formally assume the role on January 1, 2026
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
Subscribe To Our Newsletter & Stay Updated